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Abstract: Since its discovery in 1920, a great deal of effort has gone into investigating the physiological
actions of vitamin D and the impact its deficiency has on human health. Despite this intense
interest, there is still disagreement on what constitutes the lower boundary of adequacy and on the
Recommended Dietary Allowance. There has also been a major push to elucidate the biochemistry of
vitamin D, its metabolic pathways and the mechanisms that mediate its action. Originally thought
to act by altering the expression of target genes, it was realized in the mid-1980s that some of the
actions of vitamin D were too rapid to be accounted for by changes at the genomic level. These rapid
non-genomic actions have attracted as much interest as the genomic actions and they have spawned
additional questions in an already busy field. This mini-review attempts to summarise the in vitro and
in vivo work that has been conducted to characterise the rapid non-genomic actions, the mechanisms
that give rise to these properties and the roles that these play in the overall action of vitamin D at the
cellular level. Understanding the effects of vitamin D at the cellular level should enable the design of
elegant human studies to extract the full potential of vitamin D to benefit human health.
Keywords: vitamin D; vitamin D receptor; signalling molecules; MAP kinases; protein kinase C;
vitamin D response element
1. Introduction
Vitamin D came to prominence when it was found that its deficiency underlies the pathogenesis
of rickets in children and osteomalacia in adults. Subsequent investigations revealed that its deficiency
and insufficiency, measured as serum 25-hydroxyvitamin D of <29 ng/mL, are associated with
osteoporosis and nonskeletal diseases such as autoimmune diseases, inflammatory bowel disease,
bacterial and viral infections, cardiovascular disease, cancer and neurocognitive disorders (reviewed
in [1]). Low vitamin D levels are also associated with increased risk of all-cause mortality [1].
It has been estimated that vitamin D deficiency affects approximately one billion people in the
world [2]. The major cause is thought to be our predominantly urbanized indoor lifestyle since our
main source of vitamin D is its precursor that is synthesised in the skin upon exposure to the sun
or UVB irradiation (see below). In order to increase the plasma levels of vitamin D, many have
advocated diet supplementation. Nutritionally, vitamin D can be obtained from cod liver oil, fatty
fish, eggs and vitamin D-fortified supplements. Although there is consensus for a need to maintain an
adequate body level of vitamin D, there is still disagreement on what constitutes the lower boundary
of adequacy and what constitutes adequacy or a healthy level amongst the different learned societies
and reference laboratories [1,3]. In order to increase the plasma levels of vitamin D, apart from
sun exposure, many have advocated diet supplementation and again, there is disagreement on the
Recommended Dietary Allowance (RDA) for vitamin D. To exacerbate these issues, it was recently
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reported that the Institute of Medicine had made a serious calculation error of the RDA such that these
values are greatly underestimated [4,5]. Furthermore, many factors, including age, body mass index,
ethnicity, calcium intake, oestrogen use, genetics, dietary fat content and composition, and duration
of supplementation affect the degree to which a given dose of vitamin D supplementation will raise
serum 25-hydroxyvitamin D concentrations [3]. At the other end of the spectrum, too much vitamin
D in the body may be harmful. For example, although refuted, some reports have stated that high
vitamin D levels are associated with increased risk of all-cause mortality [1]. However, other factors
may muddle the picture in situations where normal-high serum vitamin D levels have been associated
with adverse outcomes. For example, it has recently been reported that whereas African-American
men who have low vitamin D levels and are therefore at a higher risk of prostate cancer may benefit
from higher vitamin D intake, supplementation with dietary flavonoids, such as quercetin, in those
with normal vitamin D levels may increase their risk of prostate cancer [6]. Thus, much remains to be
resolved nutritionally in order to fully exploit the benefits of vitamin D and its metabolites.
The question of how vitamin D acts at the cellular level has intrigued many and this has enabled
the elucidation of the biochemistry of vitamin D and its metabolites, and an understanding of its
effects on target cells and its mode of action. Vitamin D is derived from 7-dehydrocholesterol, which is
converted in the skin under Ultraviolet light band B (UVB) to vitamin D3 (cholecalciferol), an inactive
precursor. This is then converted to the biologically active vitamin D3 metabolite, 1,25-dihydroxyvitamin
D3 (1,25D), also known as calcitriol. This secosteroid hormone plays important roles in a range of
physiological processes including Ca2+ and phosphate homeostasis and bone remodelling, cellular
proliferation and differentiation and immune regulation [7–10] Consequently, achieving an adequate
level of vitamin D in the body is important in preventing the development of the conditions discussed
above. The levels of 1,25D are tightly regulated by the mitochondrial hydroxylases, cytochromes
P450C1α (CYP27B1) and P450C24 (CYP24) that catalyse the bioactivation and degradation of vitamin
D3 metabolites, respectively [11].
2. Vitamin D and Non-Genomic Actions
Classically, the effects of 1,25D are thought to be mediated by its interaction with a nuclear
vitamin D receptor (VDRn) (Figure 1), a member of the nuclear receptor superfamily of ligand-activated
transcription factors [12]. Liganded VDRn forms a heterodimeric complex with Retinoid-X-Receptor
(RXR) and either upregulates or downregulates the expression of target genes through binding to
promoter sequences termed a vitamin D3 response element. It is recognised that 1,25D also exerts
non-genomic actions that are manifested, in the main, as the activation of signalling molecules, such
as phospholipase C and phospholipase A2 (PLA2), phosphatidylinositol-3 kinase (PI3K) and p21ras,
and the rapid generation of second messengers (Ca2+, cyclic AMP, fatty acids and 3-phosphoinositides
such as phosphatidylinositol 3,4,5 trisphosphate), accompanied by the activation of protein kinases,
such as protein kinase A, src, mitogen-activated protein (MAP) kinases, protein kinase C (PKC) and
Ca2+-calmodulin kinase II [12–16] (Figure 1). The non-genomic actions also include the opening of Ca2+
and Cl´ channels [17]. Furthermore, it has also been recognized that the VDR can exert non-classical
actions (Figure 1). These are discussed below.
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Figure 1. The non-genomic acti , . 1,25D acts via both genomic a d non-genomic acti ns
to late t e xpre sion of vitamin D responsive genes such as CY24 and those that promote
anti-microbial defenc . The non-genomic me hanisms, downstream of VDRn and/or VRDm complexed
to aveolin1, includ the activation of intracellular signalling molecules, such as PKC, PI3K, MAP
kinases, CaMKII and PLA2. The range of signalling molecules being activated is related to the
cell-type and status of cell maturation. Targets of these kinases include transcription factors, e.g.,
SP1, SP3 and RXR that bind to response elements on the promoters of vita in D-responsive genes.
Another non-genomic action of 1,25D involves the regulation of VDR binding to target proteins
such as STAT1 and IKKβ that enables the cross modulation by 1,25D of gene expression mediated
by non-vitamin D ligands, including IFN-α and TNF-α. This mechanism provides an avenue for
1,25D to directly regulate immune responses and anti-viral actions of immune and non-immune
cells. Ligation of CD40, IFN-γ receptor and TLR2/4/8 causes an upregulation of VDR and CYP27B1
expression and this facilitates an autocrine mechanism that enables the increased availability of 1,25D
and VDR to cooperate with these immune receptors for various responses, including anti-microbial
activity while modulating the expression of cytokines, chemokines and type 1 interferons. The
VDR, independently of 1,25D, can also exhibits a non-classical action that involves its interaction
with proteins such as transcription factors or kinases to modulate cellular responses, including
immune/antiviral response and stress-induced cell death. Bold arrows denote direct actions of 1,25D.
Dotted arrows denote ligand binding to their receptors. Reversible arrows indicate protein-protein
interaction. Arrows with double lines indicate kinase-substrate relationship. Abbreviations: 25D:
25-hydroxyvitamin D; 1,25D: 1,25 dihydroxyvitamin D; VDRm/n: membrane or nuclear vitamin
D receptor; CYP27B1 and CYP24: cytochromes P450C1α and P450C24; PLA2: phospholipase A2;
CaMKII: Calcium/calmodulin protein kinase II; AA: arachidonic acid; DAG: diacylglycerol; PLC:
phospholipase C; IFN: interferon; TLR: Toll-like receptor; PMA: phorbol 12-myristate 13-acetate;
PKC: protein kinas C; PI3K: phosphatidylinositol 3-kinase; Akt: protein kinase B; IKK: I-κB kinase;
MED1; Mediat r Complex Subunit 1; RXR: retin ic acid X receptor; Specificity Protein; ETS 1: Avian
Erythroblastosis Virus E26 Oncogene Homol g-1; VSE: Vitamin D stim tory element; STAT: Sig al
Transducer and Activator of Tra scription; JAK: Janus ki ase; Tyk: Tyrosine ki ase; ERK: Extracellular
sign l Regulated protein Kinas ; JNK: c-Jun N-terminal Kinase; MCP-1: Monocyte chemoattractant
protein 1; CAMP: Cathelicidin Antimicrobial Peptid ; IFI27L: Interferon, Alpha-Inducible Protein 27
like; IFI44L: Interfero -Induced Protein 44-Like; ISG15: Interf ron-Stimulated Protein, 15 KDa; OAS:
21-51-Oligoadenylate Synthetase; RSAD2: Radical S-Adenosyl Methionine Domain Containing 2; “p”
denotes phosphorylation; “+” denotes enhancement.
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3. Vitamin D Receptors
Much effort has been expended to address how the non-genomic actions are mediated, what
receptor(s) is (are) involved, whether the VDRn plays a role and how important the non-genomic
actions are to the overall response to 1,25D. A distinct membrane VDRm was originally proposed by
Norman and colleagues on the basis that some vitamin D analogues that were incapable of binding
VDRn were able to initiate the rapid responses of 1,25D [17,18]. The authors identified a specific
binding protein for 1,25D in the basal-lateral membranes of chick intestinal epithelium that regulates
Ca2+ transport across such membranes [19]. This receptor was named membrane-associated rapid
response steroid (MARRS) binding protein and it was later identified to be a protein known by
several different names: thioredoxin-like protein or GRP58 (for glucose responsive protein, 58 kDa),
endoplasmic reticulum protein 57/60 kDa (ERp57 or ERp60) and Protein Disulfide Isomerase Family
A, Member 3 (Pdia3) [12,13]. This VDRm can be visualised around the cell surface and the perinuclear
area but not in the nucleus. At the plasma membrane, the receptor is localised to the caveolae where it
binds caveolin-1 and phospholipase A2 [20,21].
4. VDRn and VDRm in Intracellular Signalling and Mechanism of Action
While the existence of a VDRm and its role in the non-genomic actions of 1,25D are well-accepted,
there has been some debate as to whether VDRn participates in the non-genomic actions of 1,25D.
Early work by Boyan and colleagues has led to the conclusion that VDRn plays no role in the activation
of PKC as by 1,25D well as some of the genomic actions of 1,25D, at least in murine growth zone
costochondral chondrocytes [22]. Thus, whereas 1,25D failed to inhibit the proliferation of VDRn-/-
cells, in contrast to its anti-proliferative action in wild-type cells, the hormone-mediated activation of
PKC and stimulation of proteoglycan synthesis appeared unaffected [22]. Employing RNA interference
(RNAi) to knock down either VDRn or Pdia3, this group has also reported that, in contrast to the
lack of dependency of PKC activity on VDRn, 1,25D-mediated activation of src and phospholipase A2
requires both the VDRm (Pdia3) and VDRn in MC3T3-E1 osteoblasts [21]. A requirement for VDRn in
the activation of signalling molecules such as the MAP kinaseas and PI3K has also been investigated.
Yamauchi et al. [23] reported that RNAi-mediated VDRn knockdown in Caco-2/TC7 cells had no effect
on the activation of ERK1/ERK2 in response to 1,25D. However, examination of their data reveals
variable degrees of ERK1/ERK2 activation in these VDRn-knockdown cells, making it difficult to draw
conclusions. In contrast, studies using C2C12 murine myoblasts in which VDRn was knocked down
by RNAi support the argument that VDRn is involved in mediating 1,25D-stimulated activation of p38
and ERK1/ERK2, src and PI3K/Akt [24]. These observations suggest that there may be a selective
usage of VDRn for distinct non-genomic/genomic signalling pathways. Nevertheless, caution may
need to be exercised in drawing the conclusion that VDRn is not required for PKC activation for two
reasons. The early work on PKC activation measured the specific activity of soluble PKC in cell lysates
relative to total cell lysate protein, rather than to total PKC protein [22]. More importantly, the need for
PKC translocation to membrane/cytoskeletal elements where the natural substrates reside [25] was not
taken into consideration using the assay. A second reason is the recent observation from the same group
of a substantial (>50%) reduction in 1,25D-stimulated PKC activity in MC3T3-E1 osteoblasts that had
had their VDRn knocked down by short hairpin RNA (shRNA) [13]. Unfortunately, there were no data
on the levels of VDRn [13] that could have helped clarify the basis for the remnant 1,25D-stimulated
PKC activity that was still evident in these shRNA-treated cells. Further work is, therefore, warranted
to ascertain whether the VDRn is coupled to PKC activation using more conventional assays.
Investigations into the mechanisms by which VDRm and VDRn initiate their actions have
revealed that, apart from its nuclear localisation, VDRn is also localized to caveolae-enriched plasma
membranes [20,21]. Under confocal microscopy, VDRn has been found at the cell surface, perinuclear
area and in the nucleus. In the caveolae of MC3T3-E1 osteoblasts, VDRn has been reported to colocalise
with VDRm (Pdia3) and caveolin-1 [21]. Co-immunoprecipitation studies have demonstrated that
although VDRn does not bind Pdia3 in these cells, it interacts with caveolin-1. In contrast, in human
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skin fibroblasts, co-immunoprecipitation studies have revealed that VDRn interacts with ERp57 or
Pdia3 [26]. As both Pdia3 and VDRn bind caveolin-1, a functional role for caveolin-1 in the action
of 1,25D is therefore likely. Indeed, knocking down the expression of caveolin-1 resulted in the loss
of non-genomic (src and PLA2 activation) as well as genomic (cell proliferation and expression of
alkaline phosphatase) actions of 1,25D in MC3T3-E1 osteoblasts [21]. These observations imply that
1,25D employs caveolin-1 as an essential scaffold to trigger its actions. Interestingly, Pdia3 and VDRn
are physically coupled to different downstream effectors. Thus, Pdia3 was found to bind caveolin-1
and PLA2 activation protein that is required for PLA2 activation whereas VDRn was found to bind
caveolin-1 and src [21]. Despite this difference, both receptors are essential for the activation of src and
PLA2 since shRNA-mediated knocked down of either Pdia3 or VDRn abrogated the activation of both
src and PLA2 [21]. Studies in MC3T3-E1 osteoblasts have also demonstrated that upon stimulation
with 1,25D, VDRn moves from the caveolae to the nucleus but no such movement is evident for
Pdia3 [21]. This shift would enable VDRn to execute its genomic function in the presence of 1,25D.
5. Regulation of 1,25D-Mediated Gene Transcription by Non-Genomic Actions
An interesting question which arose following the acceptance of the rapid non-genomic actions
was whether these could modulate the genomic function of 1,25D. Indeed, there is strong evidence
for this. As discussed above, 1,25D causes the activation of signalling molecules such as MAP
kinases, including ERK1/ERK2, ERK5 and JNK1/JNK2, and others such as PKC, PI3K, PLA2 and
p21ras [12–17,27,28]. A range of studies have investigated the roles these play in the genomic function
of 1,25D. Studies into the anti-cancer actions of 1,25D have demonstrated that 1,25D induces the
differentiation of acute myeloid leukemia cell lines to more mature cells of the monocytic lineage [28].
In these cells, 1,25D up-regulates the activity of ERK1/ERK2 as well as the expression and activation of
ERK5. It appears that activation of ERK5 but not ERK1/ERK2 restrains the 1,25D-induced maturation
programme since inhibition of ERK5 but not ERK1/ERK2 enabled the cells to mature further along the
lineage to display macrophage-like phenotype [28]. This raises the possibility that inhibition of ERK5
would enhance the anti-cancer action of 1,25D and implies that some of the non-genomic action may
negatively impact on the action of the secosteroid hormone. However, the role and involvement of the
each signalling molecule in mediating the actions of 1,25D may be dependent on the cell-type and/or
function under investigation as discussed below.
In growth zone costochondral chondrocytes, ERK1/ERK2 have been reported to be involved in
regulating proteoglycan synthesis in response to 1,25D as kinase inhibition resulted in suppression of
this response [29]. Inhibition of the ERKs had little or no effect on 1,25D-mediated enhancement of the
specific activity of alkaline phosphatase or the inhibition of chondrocyte proliferation. In cells derived
from the kidney, the main site for 1,25D inactivation, MAP kinases, such as ERK1/ERK2, JNK1/JNK2
and ERK5, PKC, PI3K and p21ras, have been found to regulate the 1,25D-mediated activation of
the CYP24 promoter [14–16,30]. These studies have also identified cell-type-specific, gene-specific
and maturation stage-specific involvement and roles for these kinases in mediating the actions of
1,25D. In monkey kidney fibroblast COS-1 cells transfected with the rat CYP24 promoter-luciferase
construct, Dwivedi et al. [14] reported that ERK1/ERK2 and ERK5 were required for 1,25D-mediated
activation of the CYP24 promoter since a dominant negative mutant of either ERK1 or MEK5, the
upstream regulator of ERK5, attenuated this response; the p38 and JNK kinases were not required.
Studies with a dominant negative p21ras mutant revealed that p21ras was upstream of the ERK
MAP kinases and required for the genomic action of 1,25D. Overall, the data show that the rapid
activation of ERK1/ERK2 and ERK5 is involved in regulating the slower 1,25D-mediated CYP24
promoter activation by phosphorylating RXRα and Ets-1, respectively, thus affecting their ability
to act via the vitamin D3 response element and the Ets-binding site, respectively, within the CYP24
promoter region [14]. ERK1/ERK2 and ERK5 are also involved in regulating the 1,25D-mediated
CYP24 promoter activation and gene expression in Caco 2 enterocyte-like cells [30]. Interestingly, ERK5,
by phosphorylating Ets-1, enhanced 1,25D-mediated CYP24 gene transcription only in proliferating
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but not differentiated Caco-2 cells [30]. An explanation for this is that differentiated cells have reduced
levels of ERK5 and Ets-1 protein compared to proliferating cells. Furthermore, in this cell-type,
ERK1/ERK2 inhibition did not affect 1,25D-regulated expression of the transient receptor potential
cation channel, subfamily V, member 6 (TRPV6) [30]. Through chromatin immunoprecipitation assays
and inhibition of ERK1/ERK2, it was found that ERK1/ERK2 targeted Mediator Complex Subunit 1
that was recruited to the CYP24 but not the TRPV6 promoter in response to 1,25D [30]. These data
provide evidence of gene-specific and cell stage-specific roles for the ERK1/ERK2 MAP kinases on
1,25D-mediated gene induction in Caco-2 cells.
Selective usage of the MAP kinases by 1,25D on CYP24 promoter activation is observed in human
embryonic kidney 293T cells. Nutchey et al. [15] reported that 1,25D induction of CYP24 required JNK
but not the ERK1/2 in these cells, in contrast to COS-1 cells [14]. Thus, blocking the JNK pathway with
a dominant negative mutant of MAP kinase ERK kinase (MKK) 4, an upstream kinase of JNK, caused
a reduction in the level of induction whereas a dominant-negative ERK1 mutant had no effect [14].
Consistent with this, 1,25D stimulation resulted in enhanced activity of JNK but not ERK1/ERK2 in
these cells. Nevertheless, ERK1/ERK2 was involved in mediating the well-known phenomenon of
synergistic up-regulation of CYP24 expression by phorbol 12-myristate 13-acetate (PMA) and 1,25D.
Thus, PMA-stimulated activation of ERK1/ERK2 was not only potentiated by 1,25D (Figure 1), which
on its own had no effect on kinase activity, but transfection of a dominant-negative ERK1 mutant
resulted in a reduced level of synergy on the activity of a CYP24 promoter-luciferase construct [15]. The
ERK1/ERK2 pathway has also been reported to underpin this synergy in differentiated Caco-2 cells and
the transcription factor, Sp3, appears to be another target of ERK1/ERK2 in mediating this synergy [31]
(Figure 1). This is supported by the observations that PMA stimulated the phosphorylation of Sp3 and
that inhibition of ERK1/ERK2 not only reduced the degree of synergy between PMA and 1,25D on
CYP24 promoter reporter activity but also PMA-stimulated phsophoryation of Sp3 [31]. The role of
Sp3 was confirmed by the observation that knockdown of Sp3 reduced the degree of enhancement of
CYP24 promoter activity by PMA [31]. The JNK and p38 modules also play a role in supporting this
synergy. Thus, it was reported that the duration of JNK activation in response to 1,25D was not only
prolonged by PMA treatment but that blocking the JNK module with a dominant negative mutant of
MKK4, reduced the degree of synergy [15]. The target of JNK was an as yet unidentified factor that
binds to a 51-TGTCGGTCA-31 sequence, termed the vitamin D stimulatory element (VSE), located
30 bp upstream of the vitamin D response element-1 in the CYP24 proximal promoter [15] (Figure 1).
In differentiated Caco-2 cells, p38 was found to be activated by PMA although the study did not
report on the effect of 1,25D on this MAP kinase [31]. Nevertheless, pharmacological inhibition of p38
attenuated both the 1,25D-induction of the CYP24-luciferace reporter construct, as well as the synergy
between PMA and 1,25D [31]. Thus, there is cell-type-specific involvement and roles of different MAP
kinases on 1,25D-mediated induction of the same gene.
In Madin Darby bovine kidney MDBK epithelial cells, Simboli-Campbell reportedthat 1,25D
caused the translocation of PKCα to the plasma membrane and PKCβ to the nucleus, albeit with
delayed kinetics compared to those observed when cells are stimulated via other classes of membrane
receptors [32]. Other PKC isozymes were unaffected. As PKCβ translocation was accompanied
by an increase in nuclear protein phosphorylation, it was proposed that PKCβ was responsible for
1,25D-mediated nuclear events [32]. This is consistent with our observation in HEK293T cells that
1,25D acted via PKCβ1, as well as PKCξ, to induce the activation of the CYP24 promoter as transfection
with a dominant negative mutant of either PKC isozyme suppressed 1,25D induction of the CYP24
promoter [15,16]. The data also show that 1,25D rapidly stimulated PI3K activity which was required
for both the 1,25D-mediated activation of PKCξ and the PKCξ-dependent phosphorylation of Sp1 that
acted via the GC box in the CYP24 promoter region [16]. Overall, these data provide strong evidence
for a role of the non-genomic actions in underpinning the genomic actions of 1,25D and reveal some
of the mechanisms via which the above-discussed signalling molecules modulate the expression of
1,25D-responsive genes.
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6. Non-Classical, Non-Genomic Action of the VDR that Involves Protein-Protein Interaction to
Regulate Gene Transcription
While the major focus on the non-genomic actions of 1,25D has centred on the signalling pathways
that are activated by VDRn and VDRm, there is another mechanism via which, 1,25D, through
a non-classical, VDRn-mediated non-genomic action, affects intracellular signalling molecules or
transcription factors that influence the expression of a variety of genes. This action may explain
some of the modulatory effects that 1,25D exerts on the innate and adaptive immunity, anti-viral
responses of cells and cell survival. In general, this involves protein-protein interaction between
the VDR and a target protein. Such targets include I-κB kinase (IKK)β, one of the upstream
regulators of the canonical NF-κB pathway [33], Signal Transducers and Activators of Transcription
(Stat)1 [34], Runt-related transcription factor (RunX)1 [35], c-jun [36], β-catenin [37], cAMP response
element-binding protein [38]. Some examples are described below to illustrate this action.
Many studies have shown that 1,25D down-regulates the expression of immune modulatory
molecules such as interleukin (IL)-12, IL-8, monocyte chemoattractant protein-1, plasminogen
activator inhibitor-1 and angiotensinogen (involved in inflammation associated hypertension), and
microRNA-155 (a negative regulator of the expression of suppressor of cytokine signalling 1) by
inhibiting NF-κB [39–43]. These effects are unlikely to involve the vitamin D response element. Instead,
the liganded VDRn has been reported to down-regulate gene transcription by directly interacting with
the key signaling molecule, IKKβ [33]. Such interaction was found to prevent IKKβ phosphorylation
on S177/181 that is believed to be needed for IKK signalosome complex formation and the downstream
phosphorylation and degradation of I-κBα [33], a prerequisite step in the activation of NF-κB. In T cells,
1,25D is known to suppress a number of T-helper (Th)1 and Th17 functions (reviewed in [35]). Thus,
1,25D has been reported to inhibit the transcription of IL-2, IFN-γ and IL-17A. Whereas inhibition
of IFN-γ expression is mediated by a genomic action of VDR/RXR complex that binds to a negative
vitamin D response element on the IFN-γ promoter, 1,25D-mediated suppression of IL-2 and IL17
expression is via a blockade of the function of key transcription factors that activate their promoters.
For example, 1,25D has been shown to block IL-2 transcription through a process that involves a
competitive binding of VDR/RXR to the Nuclear Factor of Activated T cells (NF-AT) element in the
IL-2 promoter, thus preventing NFATc1 binding. Although a direct interaction between the VDR
or VDR/RXR with NFATc1 has not been demonstrated, the VDR/RXR complex has been shown
to prevent the formation of NFATc1/AP1 complex [35]. A similar mechanism is operative in the
suppression of IL-17A production by 1,25D [35]. In addition, 1,25D also acts, in part, through a direct
sequestration of RunX1 by VDR/RXR that prevents RunX1 from binding to its site on the IL17A
promoter [35].
Although metabolites of vitamin D possess anti-hepatitis C virus (HCV) activity [44–46], albeit
not against some respiratory viruses (reviewed in [47]), 1,25D also enhances the inhibitory effect of
IFN-α on HCV replication [34]. This is consistent with the recent findings that vitamin D deficiency
is associated with poor responsiveness to pegylated IFN-α and ribavirin therapy in patients with
chronic hepatitis C [44,48]. The antiviral activity of IFN-α involves the Janus kinase (Jak)-STAT
signalling pathway and activation of JAK1 and Tyk2 results in the phosphorylation of Stat1 and Stat2,
transcription factors which are critical for the expression of interferon (IFN)-stimulated genes [34]. In
the absence of 1,25D, Lange et al. [34] found a constitutive inhibitory interaction between VDRn and
Stat1 in a hepatocellular carcinoma cell line. Stimulation with 1,25D and IFN-α released this binding.
Although 1,25D did not affect the degree of IFN-α-induced phosphorylation of Stat-1, 1,25D enhanced
the IFN-α-induced binding of phosphorylated Stat1 to its IFN-γ activated DNA target sequences
and enhanced the expression of IFN-stimulated genes, including IFI27L, IFI44L, ISG15, OAS and
RSAD2 [34]. The inhibitory role of VDR was further supported by the observation that silencing of
the VDR resulted in an enhanced expression of the above IFN-stimulated genes when the cells were
exposed to IFN-α [34]. These data provide a plausible explanation for the poor responsiveness of
vitamin D-deficient patients to pegylated IFN-α treatment.
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In addition to the above described antiviral actions of 1,25D, the secosteroid hormone also
contributes to the innate antimicrobial activity of monocytes/macrophages and other cell types. Data
from human monocytes or macrophages have revealed that activation of the cells by ligands of Toll-like
receptors 1, 2, or 8, IFN-γ or CD40 ligand, upregulates the expression of CYP27B1 and VDRn (reviewed
in [35,49,50]). This results in the bioactivation of 25 hydroxivitamin D to 1,25D by CYP27B1 [50]. Acting
via the binding of liganded VDRn to vitamin D3 response elements, this autocrine mechanism enables
1,25D to stimulate the transcription and production of anti-microbial peptides such as cathelicidin
and human β-defensin 2 (DEFB4) as well as the expression of nucleotide-binding oligomerization
domain-containing protein 2 (NOD2), which feeds back to further enhance DEFB4 expression [49,50].
Concomitantly, the liganded VDR mediates downregulation of hepcidin antimicrobial peptide that
promotes the export of iron, making the intracellular compartment unfavourable for pathogen
survival and proliferation. Furthermore, cathelicidin promotes autophagy, which would enhance
autophagolysosomal fusion and antimicrobial activity [49]. In primary human keratinocytes, although
1,25D (10´8 M) per se has been reported to be sufficient to induce cathelicidin expression, such
expression was found to be enhanced by interleukin-17A, which alone is unable to stimulate
cathelicidin expression [51]. The synergy between vitamin D metabolites and receptors of the
innate and adaptive immune systems has been implicated in the killing of Pseudomonas aeruginosa
and Bordetella bronchiseptica in bronchial epithelial cells [52], killing of intracellular Mycobacterium
tuberculosis by human macrophages and inhibition of HIV replication in macrophages [53,54], to name
a few examples. There is some evidence that a non-genomic action is involved in the induction of
the antimicrobial peptides. In keratinocytes, it has been reported that not only was the activity of
ERK1/ERK2 enhanced by either IL17A or 1,25D, with further enhancement when the two agents
were present together, but that the induction of cathelicidin was also suppressed by more than 50%
when the ERK1/ERK2 pathway was inhibited by the pharmacological inhibitor, PD98059 [51]. This
again reinforces the premise that genomic actions that involve the vitamin D3 response elements are
modulated by the non-genomic actions.
Although vitamin D possesses anti-cancer properties and 1,25D has been reported to promote the
differentiation or death of cancer cells ([1,27,28,36] and references therein), there is evidence that also
supports an anti-apoptotic function of the VDR, independently of 1,25D. For example, treatment of
human breast cancer MDA-MB-468 cells with stressors such as arsenite has been reported to result in
cell death [36]. Such treatment of cancer cells also induces the activation of p38 and JNK that results in
an upregulation of VDR expression [36,55,56]. One of the consequences of this elevated levels of VDR
is the suppression of cell death induced by arsenite, and 1,25D is not required for this action [36,55].
Support for an anti-death function of the VDR comes from the observation that stable transfection
of cancer cells with VDR confers resistance against arsenite-induced cell death [36]. Although c-jun,
by binding to a c-jun/AP1 site on the VDR promoter, is required for the arsenite-induced upregulation
of VDR expression [56], the VDR, in turn, suppresses a c-jun-dependent cell death pathway initiated
by arsenite [36]. This non-classical action of the VDR is likely to be mediated by its binding to
c-jun [36]. Interestingly, while arsenite increases the degree of this interaction, 1,25D does not affect this
phenomenon. The above examples demonstrate that the VDR can exhibit non-classical, non-genomic
actions though its ability to interact with various target proteins in the cell.
7. Effects of Vitamin D Supplementation on Intracellular Signalling
While the above discussed data were derived from in vitro studies using primary cells or
cell-lines to which 1,25D was added into the incubation medium, there is some recent evidence that
administration of cholecalciferol (vitamin D3) to animals can result in the modulation of cellular
function and intracellular signalling processes. Consistent with the in vitro data that 1,25D suppresses
inflammatory cytokine production and inhibits NF-κB mediated gene transcription [33,39–43], it has
been reported that dietary supplementation of carp with cholecalciferol suppressed lipopolysaccharide-
induced production of inflammatory markers, including tumour necrosis factor (TNF)α, IL-1β, IL-6
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and IL-8 and this was likely to have been the consequence of a vitamin D-mediated downregulation of
Toll-like receptor (TLR) 4, Myeloid differentiation primary response gene (Myd) 88 and NF-κB p65
mRNA expression [57]. In another study, Al-Rasheed et al. [58] reported that dietary supplementation
of rats with cholecalciferol suppressed cardiac hypertrophy by down regulating TNF-α production
and signalling via the NF-κB pathway as evidenced by a reduction in p65 expression but increased
expression of the inhibitory I-κBα at the mRNA level. An inhibitory effect of dietary supplementation
with cholecalciferol on the NF-κB pathway, muscle tissue damage and inflammatory response has also
been reported in rats that had been subjected to high intensity exercise [59]. In this study, although
the effect of 1,25D per se on the activities of ERK1/ERK2, p38 and AMP-activated protein kinase
(AMPK) was not examined, dietary supplementation with cholecalciferol prevented high intensity
exercise from increasing the activities of these kinases as well as inhibiting the activation of NF-κB.
In contrast, another study in a model of polycystic ovary syndrome has found that feeding mice with
1,25D prevented the development of cardiac abnormalities and myocardial apoptosis/dysfunction
and this was associated with a normalisation of AMPK activity in the myocardium [60]. These studies
imply that 1,25D executes non-genomic actions in vivo. Currently, there are very limited data in
humans in which tissues/cells have been examined for non-genomic actions of vitamins D following
dietary supplementation. However, there is one study comparing controls with type 1 diabetes
patients in which the authors found that low plasma 25D levels in patients were associated with
increased inflammatory markers. Thus, the patients have higher plasma C-reactive protein and higher
expression of TLR2/4 and NK-κB activity in their monocytes than controls [61]. It remains to be
determined whether increasing the levels of 25D in these patients would reduce the levels of these
inflammatory markers to demonstrate a causal relationship. Nevertheless, these data support the
idea that the beneficial effects of vitamin D in vivo are mediated, at least in part, via a non-genomic
action on intracellular signalling. Additional in vivo studies are warranted to determine whether
1,25D per se exerts the same effects on the intracellular signalling molecules/pathways that had been
investigated under in vitro conditions. Furthermore, it is also unclear whether blocking the activities of
the kinases/pathways can prevent the secosteroid hormone from exerting its effects in vivo. A greater
understanding of how 1,25D acts in vivo would not only open avenues to modulate the actions of 1,25D
for therapeutic purposes but also enhance confidence in the use of vitamin D3 as dietary supplements
or for nutraceutical purposes. For example, understanding the actions of 1,25D at the signalling
level in vivo would enable its actions to be pharmacologically manipulated. This will be relevant to
situations when CYP27B1 is over-expressed in disease-activated macrophages that results in high levels
of 1,25D and increased risk of hypercalcemia as seen in sarcoidosis [62], or when vitamin D-mediated
antibacterial responses in monocytes in lepromatous leprosy are corrupted by IL4-induced excessive
production of CYP24 [49] that inactivates 1,25D. Similarly, the more classical actions of 1,25D on
Ca2+ and phosphate homeostasis and bone remodelling, cellular proliferation and differentiation and
immune regulation [7–10] could be manipulated, based on this understanding.
In summary, 1,25D has come a long way from its originally reported role in Ca2+ and phosphate
homeostasis and its deficiency in the pathogenesis of rickets in children and osteomalacia in adults.
At the same time, its mode of action has deviated from one that is reliant on just the VDRn to effect its
genomic function to the acceptance of a VDRm and a role of non-genomic actions in regulating a wide
range of 1,25D-mediated genomic and cellular functions that impact on general physiological processes,
including bone remodelling, cellular proliferation and differentiation, and others such as immune
regulation, and anti-cancer and anti-viral/bacterial activities. Several modes of action downstream of
VDR ligation by the secosteroid hormone have been identified. However, to fully exploit the potential
of 1,25D as a wide-spectrum regulator of human physiology, defining an appropriate minimal level
and achieving this level in the body, either through diet or sun exposure, remains a challenge in
sections of the population. A better understanding of the non-genomic actions of 1,25D may provide
avenues to modulate its actions, particularly in those who are vitamin D-deficient.
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Abbreviations
The following abbreviations are used in this manuscript:
RDA Recommended Dietary Allowance
25D 25-hydroxyvitamin D
1,25D 1,25 dihydroxyvitamin D






MAP kinase Mitogen-activated protein kinase
PKC Protein kinase C
MARRS Membrane-associated rapid response steroid
GRP58 Glucose responsive protein, 58 kDa
ERp57 and ERp60 Endoplasmic reticulum protein 57/60
Pdia3 Protein Disulfide Isomerase Family A, Member 3
RNAi RNA interference
Akt Protein kinase B
shRNA Short hairpin RNA
ERK Extracellular signal Regulated protein Kinase
JNK c-Jun N-terminal Kinase
TRPV6 Transient receptor potential cation channel, subfamily V, member 6
MKK MAP kinase ERK kinase
PMA Phorbol 12-myristate 13-acetate




NFAT Nuclear factor of activated T cells
RunX Runt-related transcription factor
AP1 Activator protein 1
IFN Interferon
HCV Hepatitis C virus
IFI27L Interferon, Alpha-Inducible Protein 27 like
IFI44L Interferon-Induced Protein 44-Like
ISG15 Interferon-Stimulated Protein, 15 KDa
OAS 21-51-Oligoadenylate Synthetase
RSAD2 Radical S-Adenosyl Methionine Domain Containing 2
AMPK AMP-activated protein kinase
TLR Toll-like receptor
DEFB4 Human β-defensin 2
TNF Tumour necrosis factor
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